Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in china

CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19

-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China

-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China

CANbridge Consolidates Gene Therapy Portfolio

-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School

-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases

CANbridge Congratulates Mirum on EU Marketing Approval for  Maralixibat/LIVMARLI® to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome

-Together with recent positive topline Phase 3 data in progressive familial intrahepatic cholestasis (PFIC), approval underscores maralixibat potential as promising new rare liver disease treatment

-CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China part of global trial ongoing in biliary atresia (BA）

CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis

Article from PhIRDA｜Bi Jingquan: To encourage the R&D of drugs for rare diseases, we need to study and formulate special policies that conform to the characteristics of rare diseases

CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease

- Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)

- CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China trial ongoing in biliary atresia (BA)

CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress